CW Advisors LLC Has $5.50 Million Stock Position in Novartis AG $NVS

CW Advisors LLC raised its holdings in shares of Novartis AG (NYSE:NVS) by 17.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 49,331 shares of the company’s stock after acquiring an additional 7,302 shares during the quarter. CW Advisors LLC’s holdings in Novartis were worth $5,499,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in NVS. Martin Investment Management LLC boosted its holdings in Novartis by 2.5% during the first quarter. Martin Investment Management LLC now owns 232,753 shares of the company’s stock worth $25,947,000 after purchasing an additional 5,670 shares during the last quarter. Osterweis Capital Management Inc. lifted its position in Novartis by 2.8% during the 1st quarter. Osterweis Capital Management Inc. now owns 87,194 shares of the company’s stock worth $9,720,000 after buying an additional 2,412 shares in the last quarter. Colonial Trust Advisors boosted its stake in shares of Novartis by 355.2% during the 1st quarter. Colonial Trust Advisors now owns 2,276 shares of the company’s stock worth $254,000 after buying an additional 1,776 shares during the last quarter. RWA Wealth Partners LLC grew its holdings in shares of Novartis by 2.3% in the 1st quarter. RWA Wealth Partners LLC now owns 9,782 shares of the company’s stock valued at $1,091,000 after acquiring an additional 217 shares in the last quarter. Finally, Qtron Investments LLC grew its holdings in shares of Novartis by 10.5% in the 1st quarter. Qtron Investments LLC now owns 11,759 shares of the company’s stock valued at $1,311,000 after acquiring an additional 1,114 shares in the last quarter. Institutional investors own 13.12% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Morgan Stanley raised Novartis from an “underweight” rating to an “equal weight” rating and set a $123.00 price target for the company in a research report on Friday, August 8th. Wall Street Zen cut Novartis from a “strong-buy” rating to a “buy” rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Novartis presently has an average rating of “Hold” and an average price target of $123.50.

Novartis Stock Up 0.1%

NVS opened at $126.9410 on Friday. The stock’s fifty day simple moving average is $119.37 and its 200 day simple moving average is $113.71. Novartis AG has a 1-year low of $96.06 and a 1-year high of $128.03. The stock has a market cap of $268.15 billion, a PE ratio of 18.48, a price-to-earnings-growth ratio of 1.78 and a beta of 0.62. The company has a current ratio of 0.82, a quick ratio of 0.62 and a debt-to-equity ratio of 0.53.

Novartis (NYSE:NVS) last released its quarterly earnings data on Thursday, July 17th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.38 by $0.04. The firm had revenue of $14.05 billion for the quarter, compared to the consensus estimate of $13.94 billion. Novartis had a net margin of 25.64% and a return on equity of 41.08%. The company’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.97 earnings per share. As a group, research analysts expect that Novartis AG will post 8.45 earnings per share for the current year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.